Clinical Trials Logo
  1. Home
  2. Primary Open Angle Glaucoma
  3. NCT00947869
  4. Details
NCT00947869 Clinical Trial

Contrast Sensitivity in Glaucoma

Primary Open Angle Glaucoma Clinical Trial

Official title:
Glaucoma Including Pseudoexfoliation Syndrome (SFB 539)

Clinical Trial Details — Status: Recruiting

Administrative data
NCT number NCT00947869
Other study ID # DFG-SFB539-H
Secondary ID
Status Recruiting
Phase N/A
First received July 27, 2009
Last updated July 27, 2009
Start date April 2009

Study information
Verified date July 2009
Source University of Erlangen-Nürnberg Medical School
Contact Anselm G Juenemann, Prof.
Email anselm.juenemann@uk-erlangen.de
Is FDA regulated No
Health authority Germany: Ethics Commission
Study type Observational

Clinical Trial Summary

The primary aim of the Erlangen´s Glaucoma Contrast Sensitivity-Study (EGCS-Study) is the evaluation of the diagnostic and prognostic validity of a diagnostic procedure, measuring contrast sensitivity. No therapeutic studies are performed.

Recruitment information / eligibility
Status Recruiting
Enrollment 30
Est. completion date
Est. primary completion date
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Both
Age group 18 Years and older
Eligibility - Patients: Primary open angle glaucoma, secondary open angle glaucoma due to PEX

- Healthy volunteers (for reliability analysis)

Inclusion Criteria:

- Age > 18

- Best corrected visual acuity 0.8 or better

- European

Exclusion Criteria:

- eye diseases: Infantile glaucoma, angle glaucoma, secondary open angle glaucoma, wich are not due to PEX, diseases involving retina, condition after ophthalmological operations or trauma, cataract, diseases concerning the refractive system, age-related macular degeneration, diabetic retinopathy, optic neuropathy (MS, neuritis), amblyopia

- Any neurological diseases

- Systemic diseases with potentially ocular involvement (e.g., diabetes mellitus)

- Systemic drugs with potentially ocular involvement

- ocular drugs

Study Design

Observational Model: Cohort, Time Perspective: Prospective

Related Conditions & MeSH terms

Locations
Country Name City State
Germany University Eye Hospital Erlangen Bavaria

Sponsors (1)
Lead Sponsor Collaborator
University of Erlangen-Nürnberg

Country where clinical trial is conducted

Germany, 

See also
  Status Clinical Trial Phase
Recruiting NCT05564091 - Cataract Surgery in Conjunction With Ab-interno Canaloplasty Compared to Cataract Surgery Only in Patients With Mild to Moderate Primary Open-Angle Glaucoma N/A
Recruiting NCT02792803 - A Comparison of Xalatan (Latanoprost) to Apo-latanoprost and Co-latanoprost in the Treatment of Glaucoma Phase 4
Terminated NCT02801617 - Non-inferiority of PRO-067 Ophthalmic Solution vs GAAP Ofteno® in Glaucoma or Ocular Hypertension Phase 3
Completed NCT01384149 - EXTERNAL SLT Treatment in Patients With Uncontrolled OPEN ANGLE GLAUCOMA Phase 1
Completed NCT00300079 - Study of the Intraocular Pressure (IOP)-Lowering Efficacy of Azopt 1.0% Compared to Timolol 0.5% in Patients With Glaucoma or Ocular Hypertension Phase 4
Enrolling by invitation NCT00221923 - African Descent and Glaucoma Evaluation Study
Recruiting NCT05605743 - Alternate Nostril Breathing Training in Geriatrics With Glaucoma and High Blood Pressure N/A
Completed NCT04828057 - Preservative-free Fixed-dose Combination of Tafluprost 0.0015% / Timolol 0.5% in Patients With Open-angle Glaucoma or Ocular Hypertension: Clinical Effectiveness, Tolerability and Safety in a Real World Setting
Completed NCT01442896 - STudy to Assess Rapid Disease Progression by Clinical and Genetic Factors In Glaucoma patientS That Are High Risk
Enrolling by invitation NCT05557721 - Uddevalla Skövde Transscleral Micropulse Study
Recruiting NCT04595227 - Glaucoma Screening Using Dynamic Analysis of Computerized Pupillary Light Reflex Assessment Device
Terminated NCT04141865 - Effect of Xen Implantation on the Aqueous Humor Proteome
Completed NCT01979913 - An Open, Non-randomized Pilot Study on the Effect of Preservative Free Tafluprost (Saflutan® Augentropfen) in Patients With Ocular Hypertension or Primary Open Angle Glaucoma With an Uncontrolled Intraocular Pressure of 30 mmHg and More Phase 4
Completed NCT01943721 - A Study of the VISION5 Product in Patients With Glaucoma or Ocular Hypertension Phase 1
Not yet recruiting NCT01711177 - Effect of Travoprost 0.004% on Retinal Oximetry in Primary Open Angle Glaucoma N/A
Completed NCT02023242 - Comparing Effectiveness of the Hydrus Microstent (TM) to Two iStents to Lower IOP in Phakic Eyes N/A
Completed NCT01769521 - Relationship Between 24-hour IOP Pattern and the 24-hour Blood Pressure Pattern in Patients With POAG N/A
Recruiting NCT00773877 - Comparison of Retinal Nerve Fiber Layer (RNFL) Thickness Measurements by Time-Domain and Spectral-Domain OCT In Glaucoma Patients N/A
Recruiting NCT00773123 - Efficacy of Retinal Nerve Fiber Layer (RNFL) / Ganglion Cell Layer Thickness Ratio by RT-View Utilizing Spectral -Domain Technology as a Diagnostic Predictor of Glaucoma. N/A
Completed NCT02544646 - Changes in Ocular Rigidity After Trabeculectomy in Patients With POAG N/A